Company intelligence / Profile preview

Aayam Therapeutics

San Jose, California, United Statesaayamtx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Aayam Therapeutics has developed ATX-003, a compound for on-demand defecation in patients with constipation and functional bowel disorders, which has been licensed to Dignify Therapeutics. The program is described as 'significantly de-risked' but specific clinical results or outcomes are not detailed, suggesting early/pre-clinical development.[1][7][8]

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

ATX-003

Pre-clinical

Indications: Constipation, Functional bowel disorders

Partnerships

Dignify Therapeutics

Beyond the preview

Go deeper on Aayam Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aayam Therapeutics.

Explore the full profile